Genomics of Inflammation and Immunity


We use high-throughput genetic and genomic screens, plus immunological assays, to identify drug targets and deliver personalised medicine for patients with immune-mediated disease, with a particular focus on inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC).

What we are doing

Genetics

We perform large scale sequencing of human genomes to identify genetic variants influencing immune-mediated diseases (e.g. IBD and PSC) and immune responses in health (e.g. following vaccination).

Genomics

We undertake single-cell sequencing of blood samples and gut biopsies in health and disease, and couple this with our DNA sequence data, to identify genetic variants that affect gene-expression in all cell-types of these disease relevant tissues.

Immunology

In our wet lab we perform high-throughput screens (e.g. CRISPR screens) and cellular assays to understand the biological mechanisms via which disease-associated variants mitigate risk and affect drug response.